SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Five-Year Lecanemab Data Presented at CTAD 2026

New long-term extension data on lecanemab in early Alzheimer's disease were presented at CTAD 2026. The supplied text says treatment benefits accrue over time.

BIIB

Related stories